At a glance
ClinicalIndex Comparison RecordN/ACompleted· 314 enrolled
Drug / intervention
Sunitinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol
In Brief
A clinical study evaluating Sunitinib for Solid Tumors. Completed, enrolled 314 participants across 59 sites in 11 countries.
Detailed Summary
The objective of this protocol is to provide SU011248 treatment for patients who have participated in a SU011248 protocol and are eligible to enter this protocol
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumors
CountriesAustralia, Canada, France, Greece, Italy, Netherlands, Singapore, Sweden, Switzerland, United Kingdom, United States
Collaborators--
Timeline
N/ACompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2004
First PostedNov 2008
Primary CompletionDec 2011
TodayJul 2026
First PostedNov 26, 2008
Enrollment StartMar 1, 2004
Primary CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 7.8 yearsPosted 17.6 years ago
Interventions
Sunitinibdrug
Sunitinib dose varies according to the doses allowed in previous protocol. It is given once a day, orally with various schedules depending on the parent protocol